Article
Maui, Hawaii - Nodal staging with sentinel lymph node biopsy (SLN) is warranted in all patients with malignant melanoma at risk for nodal metastasis, and patients with a positive SLN should undergo therapeutic lymph-node dissection and be counseled about the opportunity for adjuvant therapy with interferon alfa-2b (Intron A) or participation in ongoing clinical trials, Kelly M. McMasters, M.D., Ph.D, said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.